Date: 2015-06-24
Type of information: R&D agreement
Compound:
Company: Ayoxxa Biosystems (Germany) Grünenthal (Germany)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease: pain
Details: * On June 24, 2015, Ayoxxa Biosystems and Grünenthal have completed a first research collaboration to validate detection limits for a biomarker based on Ayoxxa’s innovative proprietary technology platform. The focus of this study was to analyze an inflammation marker at very low concentrations released from human cells following treatment in cell culture experiments. This new approach aims to develop improved methods for clinical biomarker detection in order to accelerate the development of new drugs for Pain and Inflammation treatment. Grünenthal provided proprietary samples while Ayoxxa contributed in-depth experience in immunoassay development to simultaneously detect multiple targets down to single digit picogramm/mL concentrations. Applications include biological samples with very low initial volume, previously inaccessible by other immunoassays. Protein multiplex analysis for highly valuable samples will open new strategies to improve clinical diagnostic and treatment development optimized for individual patients’ needs.
Financial terms:
Latest news:
